Abstract:Gemcitabine, a clinically effective nucleoside anticancer agent, is a polar drug with low membrane permeability and is administered intravenously. Further, extensive degradation of gemcitabine by cytidine deaminase to an inactive metabolite in the liver affects its activity adversely. Thus, strategies that provide both enhanced transport and high metabolic bioevasion would potentially lead to oral alternatives that may be clinically useful. The objective of this study was to evaluate whether amino acid ester prodrugs of gemcitabine would (a) facilitate transport across intestinal membranes or across cells that express hPEPT1 and (b) provide resistance to deamination by cytidine deaminase. 3'-Monoester, 5'-monoester, and 3',5'-diester prodrugs of gemcitabine utilizing aliphatic (L-valine, D-valine, and L-isoleucine) and aromatic (L-phenylalanine and D-phenylalanine) amino acids as promoieties were synthesized and evaluated for their affinity and direct hPEPT1-mediated transport in HeLa/hPEPT1 cells. All prodrugs exhibited enhanced affinity (IC(50): 0.14-0.16 mM) for the transporter. However, only the 5'-L-valyl and 5'-L-isoleucyl monoester prodrugs exhibited (a) increased uptake (11.25- and 5.64-fold, respectively) in HeLa/hPEPT1 cells compared to HeLa cells and (b) chemical stability in buffers, that were comparable to valacyclovir, a commercially marketed oral amino acid ester prodrug. The widely disparate enzymatic bioconversion profiles of the 5'-L-valyl and 5'-L-isoleucyl prodrugs in Caco-2 cell homogenates along with their significant resistance to deamination by cytidine deaminase suggest that the disposition of gemcitabine following oral administration would be controlled by the rate of bioconversion following transport across the intestinal epithelial membrane. The combined results also suggest that it may be possible to modulate these characteristics by the choice of the amino acid promoiety.

Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine.

Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: in Vitro and in Vivo Evaluation

Synthesis and Anticancer Evaluation of Acetylated-Lysine Conjugated Gemcitabine Prodrugs.

Sl-01, An Oral Gemcitabine Derivative, Inhibited Human Cancer Growth More Potently Than Gemcitabine

Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine

Study on the synthesis and in vitro anti-tumor activity of Gemcitabine derivative

Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevasion, and hPEPT1-Mediated Transport

Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs

Synthesis and biological activity of 2',2'-difluorodeoxycytidine (gemcitabine)

Combination of L-Carnitine with Lipophilic Linkage-Donating Gemcitabine Derivatives As Intestinal Novel Organic Cation Transporter 2-Targeting Oral Prodrugs.

Synthesis of a Gemcitabine Prodrug for Remote Loading into Liposomes and Improved Therapeutic Effect.

Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy

Recent Development of Prodrugs of Gemcitabine

Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs

Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine

Pharmacokinetics and Metabolism of SL-01, a Prodrug of Gemcitabine, in Rats

Striking a Balance between Carbonate/Carbamate Linkage Bond and Reduction-Sensitive Disulfide Bond-bearing Linker for Tailored Controlled Release: In Situ Covalently Albumin-Binding Gemcitabine Prodrugs Promote Bioavailability and Tumor Accumulation.

Design, synthesis and evaluation of carbamate-bridged amino acid prodrugs of cycloicaritin with improved antitumor activity, aqueous solubility and phase II metabolic stability

SL-01, an Oral Derivative of Gemcitabine, Inhibited Human Breast Cancer Growth Through Induction of Apoptosis.

A self-assembling prodrug nanosystem to enhance metabolic stability and anticancer activity of gemcitabine

Involvement of CYP4F2 in the Metabolism of a Novel Monophosphate Ester Prodrug of Gemcitabine and Its Interaction Potential In Vitro.